Different effects of nitric oxide synthase inhibitors on convulsions induced by nicotine in mice

Pharmacological Reports

Volumn 59, Issue 3, 2007, Pages 259-267

  Tutka, Piotr ^a   Barczyński, Bartłomiej ^a   Arent, Katarzyna ^a   Mosiewicz, Jerzy ^a   Mróz, Tomasa ^a   Wielosz, Marian ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

7 nitroindazole; Aminoguanidine; NG nitro L arginine; Nicotine; Nitric oxide; Seizures

Indexed keywords

7 NITROINDAZOLE; AMINOGUANIDINE; ARGININE; INDUCIBLE NITRIC OXIDE SYNTHASE; N(G) NITROARGININE; NEURONAL NITRIC OXIDE SYNTHASE; NICOTINE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; INCIDENCE; MALE; MOUSE; NONHUMAN; TREATMENT OUTCOME;

EID: 34548154315     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Aceto MD: The antinicotinic effects of drugs with clinically useful sedative-antianxiety properties. Pharmacology, 1975, 13, 458-464.
2. Alexander CB, Elmore TM, Kokate TG, Kirkby RD: Further studies on anti- and proconvulsant effects of inhibitors of nitric oxide synthase in rodents. Eur J Pharmacol, 1998, 344, 15-25.
3. Bastlund JF, Berry D, Watson WP: Pharmacological and histological characterization of nicotine-kindled seizures in mice. Neuropharmacology, 2005, 48, 975-983.
4. Benowitz NL: Nicotine addiction. Prim Care, 1999, 26, 611-631.
5. Borowicz KK, Kleinrok Z, Czuczwar SJ: Influence of 7-nitroindazole on the anticonvulsive action of conventional antiepileptic drugs. Eur J Pharmacol, 1997, 331, 127-132.
6. Brian JE Jr, Faraci FM, Heistad DD: Recent insights into the regulation of cerebral circulation. Clin Exp Pharmacol Physiol, 1996, 23, 449-457.
7. Buisson A, Lakmeche N, Verrecchia C, Plotkine M, Boulu RG: Nitric oxide: an endogenous anticonvulsant substance. Neuroreport, 1993, 4, 444-446.
8. Castagnoli K, Palmer S, Anderson A, Bueters T, Castagnoli N Jr.: The neuronal nitric oxide synthase inhibitor 7-nitroindazole also inhibits the monoamine oxidase-B-catalyzed oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Chem Res Toxicol, 1997, 10, 364-368.
9. G-nitro-L-arginine impairs the anticonvulsive action of ethosuximide against pentylenetetrazol. Eur J Pharmacol, 1999, 366, 137-142.
10. Damaj MI, Glassco W, Dukat M, Martin BR: Pharmacological characterization of nicotine-induced seizures in mice. J Pharmacol Exp Ther, 1999, 291, 1284-1291.
11. De Sarro G, Di Paola ED, De Sarro A, Vidal MJ: Role of nitric oxide in the genesis of excitatory amino acid-induced seizures from the deep prepiriform cortex. Fundam. Clin Pharmacol, 1991, 5, 503-511.
12. De Sarro G, Di Paola ED, De Sarro A, Vidal MJ: L-arginine potentiates excitatory amino acid-induced seizures elicited in the deep prepiriform cortex. Eur J Pharmacol, 1993, 230, 151-158.
13. De Sarro G, Gareri P, Falconi U, De Sarro A: 7-Nitroindazole potentiates the antiseizure activity of some anti-convulsants in DBA/2 mice. Eur J Pharmacol, 2000, 394, 275-288.
14. Dixit KS, Dhasmana KM, Saxena RC, Kohli RP: Antagonism of intracerebrally induced nicotinic convulsions in mice: A method for measuring the central antinicotinic activity of CNS acting agents. Psychopharmacology, 1971, 19, 67-72.
15. Dobelis P, Hutton S, Lu Y, Collins AC: GABAergic systems modulate nicotinic receptor-mediated seizures in mice. J Pharmacol Exp Ther, 2003, 306, 1159-1166.
16. G-nitroarginine in brain in vitro and in vivo. Biochem Biophys Res Commun, 1991, 176, 1136-1141.
17. G-nitro-L-arginine, and D-CPPene on harmaline-induced postural tremor, N-methyl-D-aspartate-induced seizures, and lisuride-induced rotations in rats with nigral 6-hydroxydopamine lesions. Eur J Pharmacol, 1996, 299, 9-16.
18. Faraci FM, Brian JE: 7-Nitroindazole inhibits brain nitric oxide synthase and cerebral vasodilatation to N-methyl-D-aspartate. Stroke, 1995, 26, 2172-2176.
19. Fedele E, Varnier G, Ansaldo MA, Raiteri M: Nicotine administration stimulates the in vivo N-methyl-D-aspartate receptor/nitric oxide/ cyclic GMP pathway in rat hippocampus through glutamate release. Br J Pharmacol, 1998, 125, 1042-1048.
20. Fedele E, Raiteri M: In vivo studies of the cerebral glutamate receptor/NO/cGMP pathway. Prog Neurobiol, 1999, 58, 89-120.
21. Garthwaite J, Charles SL, Chess-Williams R: Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature, 1988, 336, 385-388.
22. Garthwaite J: Glutamate, nitric oxide and cell-cell signaling in the nervous system. TINS, 1991, 14, 60-67.
23. Getting SJ, Segieth J, Ahmad S, Biggs CS, Whitton PS: Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Res, 1996, 717, 196-199.
24. Guix FX, Uribesalgo I, Coma M, Muñoz FJ: The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol, 2005, 76, 126-152.
25. Han D, Yamada K, Senzaki K, Xiong H, Nawa H, Nebshima T: Involvement of nitric oxide in pentylenetetrazol-induced kindling in rats. J Neurochem, 2000, 74, 792-798.
26. Iadecola C: Regulation of the cerebral microcirculation during neural activity: is nitric oxide the missing link? Trends Neurosci, 1993, 16, 206-214.
27. Iadecola C: Bright and dark sides of nitric oxide in ischemic brain injury. Trends Neurosci, 1997, 20, 132-139.
28. Jones PA, Smith RA, Stone TW: Nitric oxide synthase inhibitors L-NAME and 7-nitroindazole protect rat hippocampus against kainate-induced excitotoxicity. Neurosci Lett, 1998, 249, 75-78.
29. Kato N, Sato S, Yokoyama H, Kayama T, Yoshimura T: Sequential changes of nitric oxide levels in the temporal lobes of kainic acid-treated mice following application of nitric oxide synthase inhibitors and phenobarbital. Epilepsy Res, 2005, 65, 81-91.
30. Kedmi M, Beaudet AL, Orr-Urteger A: Mice lacking neuronal nicotinic acetylocholine receptor beta4-subunit and mice lacking both alpha5- and beta4-subunits are highly resistant to nicotine-induced seizures. Physiol Genomics, 2004, 13, 221-229.
31. Kirkby RD, Carroll DM, Grossman AB, Subramaniam S: Factors determining proconvulsant and anticonvulsant effects of inhibitors of nitric oxide synthase in rodents. Epilepsy Res, 1996, 24, 91-100.
32. Kovach AGB, Lohinai Z, Marczis J, Balla I, Dawson TM, Snyder SH: The effect of haemorrhagic hypotension and retransfusion and 7-nitroindazole on rCBF, NOS catalytic activity, and cortical NO content in the cat. Ann NY Acad Sci, 1994, 38, 348-368.
33. Kuriyama K, Ohkuma S: Role of nitric oxide in central synaptic transmission: effects on neurotransmitter release. Jpn J Pharmacol, 1995, 69, 1-8.
34. Lallement G, Shih TM, Pernot-Marino I, Baubichon D, Foquin A, McDonough JH: The role of nitric oxide in soman-induced seizures, neuropathology, and lethality. Pharmacol Biochem Behav, 1996, 54, 731-737.
35. Lei SZ, Pan ZH, Aggarwal SK, Chen HS, Hartman J, Sucher NJ, Lipton SA: Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron, 1992, 8, 1087-1099.
36. Lipman JJ, Spencer PSJ: Rapid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods, 1980, 4, 327-333.
37. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
38. Lonart G, Wang J, Johnson KM: Nitric oxide induces neurotransmitter release from hippocampal slices. Eur J Pharmacol, 1992, 220, 271-272.
39. Łuszczki JJ, Czuczwar M, Gawlik P, Sawiniec-Późniak G, Czuczwar K, Czuczwar SJ: 7-Nitroindazole potentiates the anticonvulsant action of some second-generation antiepileptic drugs in the mouse maximal electroshock-induced seizure model. J Neural Transm, 2006, 113, 1157-1168.
40. Łuszczki JJ, Sacharuk A, Wojciechowska A, Andres-Mach MM, Dudra-Jastrzebska M, Mohamed M, Sawicka KM et al.: 7-Nitroindazole enhances dose-dependently the anticonvulsant activities of conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Pharmacol Rep, 2006, 58, 660-671.
41. Manzoni O, Prezeau L, Marin P, Deshager S, Bockaert J, Fagni L: Nitric oxide-induced blockade of NMDA receptors. Neuron, 1992, 8, 653-662.
42. Masukawa T, Nakanishi K, Natsuki R: Role of nitric oxide in the convulsions following the coadministration of enoxacin with fenbufen in mice. Jpn J Pharmacol, 1998, 76, 425-429.
43. Moncada C, Lekieffre D, Arvin B, Meldrum B: Effect of NO synthase inhibition on NMDA- and ischaemia-induced hippocampal lesions. Neuroreport, 1992, 3, 530-532.
44. Montecot C, Rondi-Reig L, Springhetti V, Seylaz J, Pinard E: Inhibition of neuronal (type 1) nitric oxide synthase prevents hyperaemia and hippocampal lesions resulting from kainate-induced seizures. Neuroscience, 1998, 84, 791-800.
45. Moore PK, Wallace P, Gaffen Z, Hart SL, Babbedge RC: Characterization of the novel nitric oxide synthase inhibitor 7-nitroindazole and related indazoles: antinociceptive and cardiovascular effects. Br J Pharmacol, 1993, 110, 219-224.
46. Mulsch A, Busse R, Mordvintcev PI, Vanin AF, Nielsen EO, Scheel-Kruger J, Olesen SP: Nitric oxide promotes seizure activity in kainate-treated rats. Neuroreport, 1994, 5, 2325-2328.
47. Paul V, Ekambaram P: Effect of 7-nitroindazole alone and in combination with phenobarbitone and diazepam on picrotoxin-induced convulsions in rats. Indian J Physiol Pharmacol, 2003, 47, 400-406.
48. Penix LP, Davis W, Subramaniam S: Inhibition of NO synthase increases the severity of kainate-induced seizures in rodents. Epilepsy Res, 1994, 18, 177-184.
49. Pereira de Vasconcelos A, Gizard F, Marescaux C, Nehlig A: Role of nitric oxide in pentylenetetrazol-induced seizures: age-dependent effects in the immature rat. Epilepsia, 2000, 41, 363-371.
50. Pereira de Vasconcelos AP, Bouilleret V, Riban V, Wasterlain C, Nehlig A: Role of nitric oxide in cerebral blood flow changes during kainate seizures in mice: genetic and pharmacological approaches. Neurobiol Dis, 2005, 18, 270-281.
51. Przegaliński E, Baran L, Siwanowicz J: The role of nitric oxide in the kainate-induced seizures in mice. Neurosci Lett, 1994, 170, 74-76.
52. Rigaud-Monnet AS, Pinard E, Borredon J, Seylaz J: Blockade of nitric oxide synthesis inhibits hippocampal hyperemia in kainic acid-induced seizures. J Cereb Blood Flow Metab, 1994, 14, 581-590.
53. Rondouin G, Bockaert J, Lerner-Natoli M: L-nitroarginine, an inhibitor of NO synthase, dramatically worsens limbic epilepsy in rats. Neuroreport, 1993, 4, 1187-1190.
54. Rundfeldt C, Koch R, Richter A, Mevissen M, Gerecke U, Löscher W: Dose-dependent anticonvulsant and proconvulsant effects of nitric oxide synthase inhibitors on seizure threshold in a cortical stimulation model in rats. Eur J Pharmacol, 1995, 274, 73-81.
55. Salas R, Cook KD, Bassetto L, De Biasi M: The alpha3 and beta4 nicotinic acetylocholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice. Neuropharmacology, 2004, 47, 401-407.
56. Shoaib M, Benwell ME, Akbar MT, Stolerman IP, Balfour DJ: Behavioural and neurochemical adaptations to nicotine in rats: influence of NMDA antagonists. Br J Pharmacol, 1994, 111, 1073-1080.
57. Segovia G, Mora F: Role of nitric oxide in modulating the release of dopamine, glutamate, and GABA in striatum of the freely moving rat. Brain Res Bull, 1998, 45, 275-279.
58. Smith SE, Man CM, Yip PK, Tang E, Chapman AG, Meldrum BS: Anticonvulsant effects of 7-nitroindazole in rodents with reflex epilepsy may result from L-arginine accumulation or a reduction in nitric oxide or L-citrulline formation. Br J Pharmacol, 1996, 119, 165-173.
59. Snyder SH: Nitric oxide: first in a new class of neurotransmitters? Science, 1992, 254, 494-496.
60. Starr MS, Starr BS: Do NMDA receptor-mediated changes in motor behaviour involve nitric oxide? Eur J Pharmacol, 1995, 272, 211-217.
61. G-nitro-L-arginine differentially affects glutamate- or kainate-induced seizures. Neuroreport, 1996, 7, 1605-1608.
62. Tutka P, Łuszczki J, Kleinrok Z, Arent K, Wielosz M: Molsidomine enhances the protective activity of valproate against pentylenetetrazole-induced seizures in mice. J Neural Transm, 2002, 109, 455-466.
63. Tutka P, Młynarczyk M, Zółkowska D, Kleinrok Z, Czuczwar SJ, Wielosz M: Nitric oxide and convulsions in 4-aminopyridine-treated mice. Eur J Pharmacol, 2002, 437, 47-53.
64. Urbańska EM, Drelewska E, Borowicz KK, Błaszczak P, Kleinrok Z, Czuczwar SJ: NG-nitro-L-arginine, a nitric oxide synthase inhibitor, and seizure susceptibility in four seizure models in mice. J Neural Transm, 1996, 103, 1145-1152.
65. Vanaja P, Ekambaram P: Demonstrating the dose- and time-related effects of 7-nitroindazole on picrotoxin-induced convulsions, memory formation, brain nitric oxide synthase activity, and nitric oxide concentration in rats. Pharmacol Biochem Behav, 2004, 77, 1-8.
66. Van Leeuwen R, De Vries R, Dzoljic MR: 7-Nitroindazole, an inhibitor of neural nitric oxide synthase, attenuates pilocarpine-induced seizures in mice. Eur J Pharmacol, 1995, 287, 211-213.